We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00089440
Recruitment Status : Unknown
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : August 6, 2004
Last Update Posted : January 11, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

August 5, 2004
August 6, 2004
January 11, 2017
June 2004
Not Provided
  • Adverse effect measures
  • pharmacokinetic assessment
Same as current
Complete list of historical versions of study NCT00089440 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
Assessment of Interactions Between IV Methamphetamine and Aripiprazole
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
Phase 1
Primary Purpose: Treatment
Amphetamine-Related Disorders
Drug: Aripiprazole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
March 2005
Not Provided

Inclusion Criteria:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact the site for more information.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP